GC Biopharma Corp.
A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
- Conditions
- Tetanus-diphtheria-acellular Pertussis (Tdap)
- Interventions
- Biological: GC3111B
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 120
- Registration Number
- NCT06997627
- Locations
- 🇰🇷
The Catholic Univ. of Korea Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
- Conditions
- Fabry Disesase
- Interventions
- Drug: HM15421/GC1134A
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 18
- Registration Number
- NCT06858397
- Locations
- 🇺🇸
David Geffen School of Medicine UCLA, UCLA Health, Los Angeles, California, United States
🇺🇸University of Kansas School of Medicine, Kansas City, Kansas, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Phase 1 Study of GC1130A in Pediatric Patients With Sanfilippo Syndrome Type A (MPS IIIA)
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 9
- Registration Number
- NCT06567769
- Locations
- 🇯🇵
National Center for Child Health and Development, Setagaya, Tokyo, Japan
🇺🇸UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions
- Conditions
- Healthy Volunteers
- Interventions
- Drug: GC2129A(Period 1)Drug: Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)Drug: Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)Drug: GC2129A(Period 2)
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 34
- Registration Number
- NCT05729386
- Locations
- 🇰🇷
H Plus YangJi Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions
- Conditions
- Healthy Volunteers
- Interventions
- Drug: GC2129A(Period 1)Drug: Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)Drug: Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)Drug: GC2129A(Period 2)
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 50
- Registration Number
- NCT05703984
- Locations
- 🇰🇷
H Plus YangJi Hospital, Seoul, Korea, Republic of
A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.
- Conditions
- Hepatitis B
- Interventions
- Biological: Diluted I.V.-Hepabig inj(GC5103)
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 105
- Registration Number
- NCT05686759
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Ajou University Medical Center, Suwon, Gyeonggi-do, Korea, Republic of
🇰🇷Inje University Haeundae Paik Hospital, Busan, Korea, Republic of
An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years
- Conditions
- Varicella Zoster Virus Infection
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 250
- Registration Number
- NCT05664152
A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient
- Conditions
- Hemophilia
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 15
- Registration Number
- NCT05493631
- Locations
- 🇰🇷
GC Biopharma Corp., Yongin-si, Gyeonggi-do, Korea, Republic of
A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ
- Conditions
- Hunter SyndromeMucopolysaccharidosis II
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 12
- Registration Number
- NCT05422482
- Locations
- 🇰🇷
Pusan National University Yangsan Hospital, Pusan, Korea, Republic of
🇰🇷Seoul National University, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of